Skip Navigation

Nephrology Dialysis Transplantation 2008 23(7):i; doi:10.1093/ndt/gfn324
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


In This Issue

The first 10% of the full text of this article appears below.

Silencing genes with antisense oligodeoxynuleotides: close to clinical application?

See editorial comment by Wang et al., pages 2115–2118

Circulating microparticles due to plasma cell membrane remodelling play an important role in vascular damage.

See editorial comment by Daniel et al., pages 2129–2132

Advanced glycation end-products (AGEs) are thought to be important mediators of structural and functional renal abnormalities in diabetic nephropathy. An in vitro . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?